Unknown

Dataset Information

0

Enhanced O-GlcNAcylation Mediates Cytoprotection under Proteasome Impairment by Promoting Proteasome Turnover in Cancer Cells.


ABSTRACT: The proteasome is a therapeutic target in cancer, but resistance to proteasome inhibitors often develops owing to the induction of compensatory pathways. Through a genome-wide siRNA screen combined with RNA sequencing analysis, we identified hexokinase and downstream O-GlcNAcylation as cell survival factors under proteasome impairment. The inhibition of O-GlcNAcylation synergistically induced massive cell death in combination with proteasome inhibition. We further demonstrated that O-GlcNAcylation was indispensable for maintaining proteasome activity by enhancing biogenesis as well as proteasome degradation in a manner independent of Nrf1, a well-known compensatory transcription factor that upregulates proteasome gene expression. Our results identify a pathway that maintains proteasome function under proteasome impairment, providing potential targets for cancer therapy.

SUBMITTER: Hashimoto E 

PROVIDER: S-EPMC7338785 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6094050 | biostudies-literature
| S-EPMC5684413 | biostudies-literature
| S-EPMC4987278 | biostudies-literature
| S-EPMC5056598 | biostudies-literature
| S-EPMC2874685 | biostudies-literature
| S-EPMC5072431 | biostudies-literature
| S-EPMC5612461 | biostudies-literature
| S-EPMC5595421 | biostudies-literature
| S-EPMC3514411 | biostudies-literature
| S-EPMC6374784 | biostudies-literature